rethinkTHC Search
Menu
Study breakdown

Haloperidol and Capsaicin Show More Promise Than Standard Anti-Nausea Drugs for CHS

ReviewModerate evidence
The takeaway

Traditional antiemetics often fail for cannabinoid hyperemesis syndrome, but haloperidol and topical capsaicin have shown promise, alongside the essential step of cannabis cessation.

emergency medicine clinicians, gastroenterologists, cannabis users experiencing cyclic vomiting

What the researchers found

Standard antiemetics like ondansetron often fail to alleviate CHS symptoms. Haloperidol and topical capsaicin have shown more promise in reducing symptoms. Cannabis cessation remains essential for resolution. The challenge of predicting who will develop CHS and reaching those resistant to stopping cannabis remains a pressing research need.

Why it matters

CHS is increasingly common as cannabis use rises, and its symptoms overlap with other GI disorders, leading to misdiagnosis and frequent ED visits. Knowing which treatments actually work can reduce unnecessary testing and improve patient outcomes.

The numbers in context

Standard antiemetics: often ineffective. Haloperidol: shows promise. Topical capsaicin: shows promise. Cannabis cessation: essential for resolution.

How the study worked

Narrative review exploring current and emerging treatments for CHS, including diagnosis challenges, treatment strategies, and research gaps.

What this study cannot tell us

Narrative review without systematic search methodology or quality assessment. Treatment evidence is based largely on case reports and small series. Cannot determine treatment effect sizes or compare treatments quantitatively.

How to read the evidence

Synthesizes current clinical knowledge from multiple sources, but narrative format without systematic methodology limits to moderate.

When this study was published

Contemporary review of CHS management literature.

The bigger picture

As cannabis use increases, CHS recognition and management become more important for emergency medicine. The inability to predict who will develop CHS means clinicians must be prepared to diagnose and manage it in any heavy cannabis user.

Questions still open

  • Can biomarkers predict who will develop CHS?
  • How can interventions reach CHS patients who are resistant to cannabis cessation?

Common questions

What is cannabinoid hyperemesis syndrome?
CHS is a condition in chronic cannabis users causing severe, recurring nausea and vomiting that standard anti-nausea medications typically cannot relieve. It resolves with cannabis cessation.
Why don't regular anti-nausea drugs work for CHS?
The mechanism of CHS differs from typical nausea. Cannabis paradoxically disrupts the gut-brain axis in ways that standard antiemetics like ondansetron do not address. Haloperidol and capsaicin target different pathways.

Read the original research

Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.

Cureus, 17(8), e90961

Citation

Smith, Shemyia A; Safwat, Mayar A; Piper, Brian J; Addison, Maame A. (2025). Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.. Cureus, 17(8), e90961. https://doi.org/10.7759/cureus.90961

Explore the wider topic